PT - JOURNAL ARTICLE AU - Asim Afaq AU - Suliman Alahmed AU - Shih-hsin Chen AU - Thabo Lengana AU - Athar Haroon AU - Heather Payne AU - Hashim Ahmed AU - Shonit Punwani AU - Mike Sathekge AU - Jamshed Bomanji TI - Impact of <sup>68</sup>Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management AID - 10.2967/jnumed.117.192625 DP - 2018 Jan 01 TA - Journal of Nuclear Medicine PG - 89--92 VI - 59 IP - 1 4099 - http://jnm.snmjournals.org/content/59/1/89.short 4100 - http://jnm.snmjournals.org/content/59/1/89.full SO - J Nucl Med2018 Jan 01; 59 AB - The objective of this study was to assess the impact of 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR). Methods: Documented management plans before and after 68Ga-PSMA PET/CT in 100 patients with BCR were retrospectively reviewed, and changes in plans were recorded. Results: Management changed after 68Ga-PSMA PET/CT in 39 patients (39%). The management changes occurred in 23 (33.8%) of 68 patients with radical prostatectomy and 16 (50%) of 32 patients previously treated with radical radiotherapy. Positive scan results (P &lt; 0.001) and higher prostate-specific antigen (PSA) levels (P = 0.024) were associated with management changes. No significant association with management change was found for Gleason grade, stage, presence of metastatic disease, PSA velocity, or PSA doubling time. Conclusion: 68Ga-PSMA PET/CT altered management in 39% of patients with BCR, and changes occurred more often in patients with radical radiotherapy treatment, positive 68Ga-PSMA scan results, and higher PSA levels.